The conjugate vaccines denotes to those vaccines which consist bacterial capsule polysaccharide or the antigen committed or conjugated to a protein. Such protein has a foremost role in developing the immunogenic feature of the polysaccharide. The conjugate vaccines are majorly utilized to vaccinate infants and children against the aggressive disease caused by the Hib bacteria, H. inflenzae, Neisseria meningitides, and streptococcus pneumoniae. The effective augment in the usage of conjugate vaccines for adults, increase in the number of the regulatory endorsements for the conjugate vaccines, increment in the prevalence of the diseases caused by the microorganisms namely Neisseria meningitides and streptococcus pneumoniae, and the advanced developments in the technology fuel the growth of the market during the short span of time.
The market for conjugate vaccines is anticipated to grow, due to the global awareness about the advantages of the vaccination for the anticipation of certain life-threatening diseases, mounting the initiatives for production of low-cost vaccines, and widespread monotonous vaccination programmes in underdeveloped economies. The market will witness a stable growth, increasing at a compound annual growth rate (CAGR) of 11.7% during reviewed period of 2017-2022, to reach approximately USD 87.7 Bn by 2022.
According to the report analysis, ‘Global Conjugate Vaccines Market (2017 - 2022)’ states that in the global conjugate vaccines market, there are numerous key players which presently functioning for leading the fastest market growth and dominating the handsome value of market share around the globe during the short span of time while developing the technologies, delivering the better consumer satisfaction, decreasing the price of the services and spreading the awareness related to the benefits of the vaccines includes GlaxoSmithKline, Pfizer Inc., Merck & Co., Novartis, Sanofi Pasteur, CSL Limited, Bharat Biotech International, Biological E Limited, Serum Institute of India and several others.
Not only has this, many of the large corporates in the global conjugate vaccine market are adopting the strategies to enlarge the business premises and investing the high amount of money for developing the services at a reasonable price and generating the high amount of money.
Based on the end user, the adult sector dominated the higher market share than the paediatric sector owing to an effective increase in the awareness on conjugate vaccines for adults, over the years. Still, the saturation level for adult conjugate vaccines is comparatively low, with the lowest being for PCVs. Hence, the growth prospective is very high. The paediatric vaccines, on the other hand is a steady market and be contingent extremely on the birth rates in each economy. The vaccination programmes, specially taken up by global organizations such as the United Nations Educational, Scientific and Cultural Organization (UNESCO), have been efficacious in eliminating several such vaccine-preventable diseases.
The Asia-Pacific region is the principal market for conjugate vaccines, which controlled a share of 42%, in 2017. The principal indicators of the probable for the vaccine market is the geriatric populace in the county, particularly in realms such as India and China. In turn, this has, invigorated market participants to augment the spending on research and development (R&D) and distribution facilities in these region. North America is the second principal market for conjugate vaccines, due to the country’s widespread immunization programmes. Therefore, in the coming years, it is anticipated that the market of conjugate vaccines will increase around the globe more positively over the coming years.
For more information, click on the link below:
Ankur Gupta, Head Marketing & Communications